316 filings
Page 7 of 16
8-K
vmvucs1k8r fzoqik
31 Mar 20
Regulation FD Disclosure
1:28pm
424B5
ktc9lcq4ccb 29
31 Mar 20
Prospectus supplement for primary offering
7:03am
8-K
fsorhhoi72vr d9qez4q
30 Mar 20
Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market
4:09pm
8-K
wfqwtn
30 Mar 20
Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
8:01am
8-K
lcyhazoscz5zkr0
20 Mar 20
Other Events
8:33am
8-K
c1t0bw5jwhpdxh
10 Mar 20
Other Events
8:33am
8-K
98ab4
18 Feb 20
Other Events
8:32am
8-K
7z1yhons3wkw071knbk
7 Feb 20
Bellerophon Announces 1-for-15 Reverse Stock Split
12:05pm
8-K
qoz7cpui10 obuuz59e3
29 Jan 20
Submission of Matters to a Vote of Security Holders
4:24pm
8-K
wj4u89x
17 Dec 19
Statistically Significant Improvement Demonstrated in Moderate to Vigorous Physical Activity
8:24am
8-K
zifm6vswh
12 Nov 19
Other Events
8:31am
8-K
z8f5295omx
7 Nov 19
Data Include New Results from Subgroup Analysis of Cohort 1 Further Demonstrating Benefits of INOpulse
8:31am
8-K
rwaas3
6 Nov 19
Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results
8:31am
8-K
o4a3boc dq
23 Oct 19
Results Presented in Late-Breaking Abstract as an Oral Presentation
8:31am
8-K
tc3nbsel7akjg
16 Sep 19
Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis
8:31am
8-K
pxej5oux
3 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1:08pm
8-K
lwcbkb369 19w
8 Aug 19
Bellerophon Provides Business Update and Reports Second Quarter 2019 Financial Results
8:32am